Stockscreener 앱 받기
20.55
0.88%
0.18
시간 외 거래:
20.55
전일 마감가:
$20.37
열려 있는:
$19.89
하루 거래량:
1.96M
Relative Volume:
1.71
시가총액:
$1.89B
수익:
-
순이익/손실:
$-804.34M
주가수익비율:
-2.1838
EPS:
-9.41
순현금흐름:
$-531.06M
1주 성능:
+11.02%
1개월 성능:
-28.00%
6개월 성능:
-59.97%
1년 성능:
-47.29%
1일 변동 폭
$19.84
$21.76
1주일 범위
$17.98
$21.76
52주 변동 폭
$15.79
$55.70
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
20.55 | 1.89B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - Bluefield Daily Telegraph
Biohaven Pharmaceutical : Announces Pricing Of $250 Million Public Offering Of Common Shares - marketscreener.com
LPL Financial LLC Raises Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Q1 Earnings Estimate for Biohaven Issued By Leerink Partnrs - Defense World
BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Morningstar
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by Alliancebernstein L.P. - Defense World
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Franklin Resources Inc. - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
Contrasting Biohaven (NYSE:BHVN) & Ampio Pharmaceuticals (NYSE:AMPE) - Defense World
Royalty Pharma expands board with Biohaven CEO appointment By Investing.com - Investing.com South Africa
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients - Benzinga
Biohaven stock hits 52-week low at $17.33 amid market challenges - Investing.com Australia
Biohaven stock hits 52-week low at $17.33 amid market challenges By Investing.com - Investing.com South Africa
Norges Bank Invests $33.71 Million in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - StreetInsider
Sei Investments Co. Purchases 24,723 Shares of Biohaven Ltd. (NYSE:BHVN) - Defense World
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - Mitrade
Corebridge Financial Inc. Acquires 2,552 Shares of Biohaven Ltd. (NYSE:BHVN) - Defense World
KLP Kapitalforvaltning AS Acquires Shares of 16,100 Biohaven Ltd. (NYSE:BHVN) - Defense World
Raymond James Financial Inc. Purchases Shares of 37,033 Biohaven Ltd. (NYSE:BHVN) - Defense World
American Century Companies boosts stake in Biohaven, ETF Daily News says - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven LtdBHVN - PR Newswire
Biohaven Ltd. Shares Tumble Amid Market Reassessment - TipRanks
Biohaven Ltd. (NYSE:BHVN) Shares Bought by American Century Companies Inc. - Defense World
Teacher Retirement System of Texas Raises Stake in Biohaven Ltd. (NYSE:BHVN) - Defense World
(BHVN) Proactive Strategies - news.stocktradersdaily.com
Biohaven stock hits 52-week low at $26.7 amid market challenges By Investing.com - Investing.com South Africa
Biohaven stock hits 52-week low at $26.7 amid market challenges - Investing.com India
Emerald Advisers LLC Acquires New Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Amundi - Defense World
Major Player in the Multiple System Atrophy (MSA) Market - openPR.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
Immunovant data positive for Biohaven, says Deutsche Bank - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
How To Trade (BHVN) - Stock Traders Daily
Biohaven’s 47% decline validates InvestingPro’s bearish Fair Value call By Investing.com - Investing.com Australia
SEC Form DEF 14A filed by Biohaven Ltd. - Quantisnow
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR
Charles Schwab Investment Management Inc. Increases Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
US Bancorp DE Raises Stock Position in Biohaven Ltd. (NYSE:BHVN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Shareholders to Connect - Markets Insider
Biohaven Ltd. Under Investigation: Levi & Korsinsky Probes Potential Securities Violations - Apna Kal
Investors who lost money on Biohaven Ltd. should contact Levi & Korsinsky about an ongoing investigationBHVN - ACCESS Newswire
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):